Annexes

• Annex 1-Members of the Management Board
• Annex 2-Members of the Committee for Medicinal Products for Human Use
• Annex 3-Members of the Pharmacovigilance Risk Assessment Committee
• Annex 4-Members of the Committee for Medicinal Products for Veterinary Use
• Annex 5-Members of the Committee on Orphan Medicinal Products
• Annex 6-Members of the Committee on Herbal Medicinal Products
• Annex 7-Committee for Advanced Therapies
• Annex 8-Members of the Paediatric Committee
• Annex 9-Working parties and working groups
• Annex 10-CHMP opinions on initial evaluations and extensions of therapeutic indication in 2024
• Annex 11-Guidelines and concept papers adopted by CHMP
• Annex 12-CVMP opinions on medicinal products for veterinary use in 2024
• Annex 13-Guidelines and concept papers adopted by CVMP
• Annex 14-COMP opinions on designation of orphan medicinal products in 2024
• Annex 15-HMPC European Union herbal monographs in 2024
• Annex 16-PDCO opinions and EMEA decisions on paediatric investigation plans and waivers in 2024
• Annex 17-Referral procedures overview 2024 – human medicines
• Annex 18-Arbitrations and referrals in 2024 - veterinary medicines
• Annex 19-Budget summaries 2023-2024
• Annex 20-European Medicines Agency establishment plan
• Annex 21-Litigation activities of EMA in 2024
• Annex 22-Access to documents requests
• Annex 23-Clinical Data Publication
• Annex 24-Publications by Agency staff members and experts in 2024

The annexes are available on EMA’s website.